Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
暂无分享,去创建一个
H. Kauczor | M. Kriegsmann | A. Stenzinger | Michael Thomas | F. Herth | C. Heussel | T. Muley | R. E. El Shafie | H. Bischoff | P. Christopoulos | H. Winter | F. Bozorgmehr | S. Rheinheimer | S. Liersch | P. Mayer | L. Gaissmaier
[1] J. Lunceford,et al. KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC , 2019 .
[2] J. Thariat,et al. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer , 2019, BMC Cancer.
[3] D. Palma,et al. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).
[4] J. Lunceford,et al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .
[5] J. Lunceford,et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials , 2019, Annals of Oncology.
[6] N. Bartolomeo,et al. The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma , 2019, Cancers.
[7] J. Lunceford,et al. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 , 2019, Annals of Oncology.
[8] Yuqing Wei,et al. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. , 2019, Translational lung cancer research.
[9] A. Stenzinger,et al. Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.
[10] C. Britschgi,et al. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. , 2019, Lung cancer.
[11] D. Reardon,et al. Efficacy and safety of immune checkpoint blockade for brain metastases , 2019, CNS oncology.
[12] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Schirmacher,et al. Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival , 2019, Cancers.
[14] Qinghua Xu,et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease , 2019, Journal of Cancer.
[15] S. Leroy,et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. , 2019, Journal of thoracic disease.
[16] A. Stenzinger,et al. Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer , 2018, Annals of Oncology.
[17] C. Gridelli,et al. Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[18] S. Leschka,et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) , 2018, Cancer Immunology, Immunotherapy.
[19] K. Syrigos,et al. Sarcoidosis‐Like Reactions Induced by Checkpoint Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] P. Iyengar,et al. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. , 2018, Journal of thoracic disease.
[21] Michael Thomas,et al. Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. , 2018, Lung cancer.
[22] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[23] S. Bonin,et al. Overview on Clinical Relevance of Intra-Tumor Heterogeneity , 2018, Front. Med..
[24] J. Wargo,et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients , 2018, Journal of Immunotherapy for Cancer.
[25] D. Camidge,et al. Reviewing RECIST in the Era of Prolonged and Targeted Therapy. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[27] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[28] J. Taube,et al. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC , 2017, Cancer Immunology Research.
[29] Chuong D. Hoang,et al. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .
[31] Ping Yang,et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.
[32] Umberto Ricardi,et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. , 2014, Clinical lung cancer.
[33] R. Doebele,et al. Clinical Investigation : Thoracic Cancer Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib , 2014 .
[34] C. Sima,et al. Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] P. Bunn,et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[36] Yukiko Nakamura,et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. , 2011, Lung cancer.
[37] A. Nagrial,et al. P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer: Topic: IT , 2017 .
[38] R. Herbst,et al. Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.
[39] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.